Evidence map›Paper›PMID 34977990›Full record

ArticleMolecular biology reports2022

Correction to: Development of a custom next-generation sequencing panel for the determination of bladder cancer risk in a Tunisian cohort.

Imen Hemissi, Sami Boussetta, Hamza Dallali, Faycel Hellal, Geoffroy Durand, Catherine Voegele, Haroun Ayed, Selim Zaghbib, Zeineb Naimi, Mouna Ayadi and 4 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Imen HemissiLaboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia.ORCID http://orcid.org/0000-0002-5435-7588
Sami BoussettaLaboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences of Tunis, Tunis, Tunisia.
Hamza DallaliPasteur Institute of Tunis, Tunis, Tunisia.
Faycel HellalNational Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia.
Geoffroy DurandCentre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France.
Catherine VoegeleCentre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France.
Haroun AyedUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Selim ZaghbibUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Zeineb NaimiMedical Oncology Department, Saleh Azaiez Institute, Tunis, Tunisia.
Mouna AyadiMedical Oncology Department, Saleh Azaiez Institute, Tunis, Tunisia.
Mohamed ChebilUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0001-8387-7593
James MckayCentre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France.ORCID http://orcid.org/0000-0002-1787-3874
Florence Le Calvez-KelmCentre International de Recherche sur le Cancer CIRC/International Agency for Research on Cancer IARC, Lyon, France.ORCID http://orcid.org/0000-0003-0063-5068
Slah OuerhaniLaboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), INSAT, National Institute of Applied Sciences and Technology of Tunis, University of Carthage, Tunis, Tunisia. slah_mekni@yahoo.fr.ORCID http://orcid.org/0000-0002-3651-4690

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34977990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.